$NMRD
Nemaura Medical Inc.

2022 Q3 Form 10-Q Financial Statement

#000107997322000965 Filed on August 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $74.03K $0.00 $320.3K
YoY Change
Cost Of Revenue $72.36K $0.00 $171.9K
YoY Change
Gross Profit $1.670K $0.00 $148.4K
YoY Change
Gross Profit Margin 2.26% 46.33%
Selling, General & Admin $2.320M $1.881M $2.022M
YoY Change 62.47% 41.19% 86.61%
% of Gross Profit 138920.36% 1362.59%
Research & Development $257.1K $330.1K $569.3K
YoY Change -10.4% 14.41% 92.29%
% of Gross Profit 15392.87% 383.69%
Depreciation & Amortization $73.89K $98.79K $90.06K
YoY Change 62.18% 173.41% 220.73%
% of Gross Profit 4424.55% 60.7%
Operating Expenses $2.577M $2.211M $2.591M
YoY Change 50.28% 36.42% 87.83%
Operating Profit -$2.575M -$2.211M -$2.443M
YoY Change 50.18% 36.42%
Interest Expense -$1.503M -$1.768M -$1.525M
YoY Change -15.53% 2.63% 40.28%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change
Pretax Income -$4.078M -$3.979M -$3.968M
YoY Change 16.72% 19.01% 60.86%
Income Tax -$350.3K
% Of Pretax Income
Net Earnings -$4.078M -$3.979M -$3.617M
YoY Change 16.72% 19.01% 69.77%
Net Earnings / Revenue -5509.45% -1129.4%
Basic Earnings Per Share -$0.16 -$0.16
Diluted Earnings Per Share -$169.2K -$165.1K -$152.0K
COMMON SHARES
Basic Shares Outstanding 24.10M shares 24.10M shares
Diluted Shares Outstanding 24.10M shares 24.10M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.11M $14.75M $17.75M
YoY Change -62.23% -52.81% -44.3%
Cash & Equivalents $10.11M $14.75M $17.75M
Short-Term Investments
Other Short-Term Assets $1.934M $1.106M $750.2K
YoY Change 41.75% -39.25% -40.91%
Inventory $1.910M $1.625M $1.488M
Prepaid Expenses
Receivables $0.00 $217.5K $101.3K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $13.95M $17.70M $20.09M
YoY Change -53.1% -48.05% -40.89%
LONG-TERM ASSETS
Property, Plant & Equipment $521.8K $603.1K $532.5K
YoY Change 48.44% 135.69% 163.42%
Goodwill
YoY Change
Intangibles $1.481M
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.949M $2.015M $2.013M
YoY Change
Total Long-Term Assets $1.949M $2.015M $2.013M
YoY Change 5.77% 24.91% 60.13%
TOTAL ASSETS
Total Short-Term Assets $13.95M $17.70M $20.09M
Total Long-Term Assets $1.949M $2.015M $2.013M
Total Assets $15.90M $19.72M $22.10M
YoY Change -49.67% -44.75% -37.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $301.1K $92.70K $136.3K
YoY Change 98.89% -14.01% -46.27%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $17.40M $16.19M $19.19M
YoY Change 9.91% 45.26% 234.68%
Total Short-Term Liabilities $20.47M $17.95M $20.58M
YoY Change 18.94% 44.48% 220.61%
LONG-TERM LIABILITIES
Long-Term Debt $3.491M $4.700M $0.00
YoY Change -60.31% -66.49% -100.0%
Other Long-Term Liabilities $955.9K $1.025M $1.053M
YoY Change -21.95% -19.07% -17.49%
Total Long-Term Liabilities $4.447M $5.725M $1.053M
YoY Change -55.62% -62.56% -94.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.47M $17.95M $20.58M
Total Long-Term Liabilities $4.447M $5.725M $1.053M
Total Liabilities $24.91M $23.67M $21.64M
YoY Change -8.5% -14.58% -19.52%
SHAREHOLDERS EQUITY
Retained Earnings -$45.79M -$41.71M -$37.73M
YoY Change
Common Stock $38.32M $38.32M $38.32M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$9.012M -$3.958M $466.1K
YoY Change
Total Liabilities & Shareholders Equity $15.90M $19.72M $22.10M
YoY Change -49.67% -44.75% -37.29%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$4.078M -$3.979M -$3.617M
YoY Change 16.72% 19.01% 69.77%
Depreciation, Depletion And Amortization $73.89K $98.79K $90.06K
YoY Change 62.18% 173.41% 220.73%
Cash From Operating Activities -$2.165M -$2.384M -$2.151M
YoY Change 21.21% 41.07% 58.35%
INVESTING ACTIVITIES
Capital Expenditures -$163.5K $25.60K -$76.47K
YoY Change -43.25% -68.87% -71.3%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$163.5K -$217.7K -$76.47K
YoY Change -43.25% -45.33% -71.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.500M -$74.28K -2.946M
YoY Change -34.78% -105.08% -115.92%
NET CHANGE
Cash From Operating Activities -2.165M -$2.384M -2.151M
Cash From Investing Activities -163.5K -$217.7K -76.47K
Cash From Financing Activities -1.500M -$74.28K -2.946M
Net Change In Cash -3.828M -$2.676M -5.173M
YoY Change -12.48% 328.46% -130.64%
FREE CASH FLOW
Cash From Operating Activities -$2.165M -$2.384M -$2.151M
Capital Expenditures -$163.5K $25.60K -$76.47K
Free Cash Flow -$2.001M -$2.410M -$2.074M
YoY Change 33.61% 35.97% 89.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 dei Entity Central Index Key
EntityCentralIndexKey
0001602078
CY2022Q2 dei Amendment Flag
AmendmentFlag
false
CY2022Q2 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
CY2022Q2 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q2 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q2 dei Document Type
DocumentType
10-Q
CY2022Q2 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q2 dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
CY2022Q2 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q2 dei Entity File Number
EntityFileNumber
001-38355
CY2022Q2 dei Entity Registrant Name
EntityRegistrantName
Nemaura Medical Inc.
CY2022Q2 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022Q2 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5027260
CY2022Q2 dei Entity Address Address Line1
EntityAddressAddressLine1
57 West 57th Street
CY2022Q2 dei Entity Address City Or Town
EntityAddressCityOrTown
Manhattan
CY2022Q2 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022Q2 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
CY2022Q2 dei City Area Code
CityAreaCode
646
CY2022Q2 dei Local Phone Number
LocalPhoneNumber
416-8000
CY2022Q2 dei Security12b Title
Security12bTitle
Common Stock
CY2022Q2 dei Trading Symbol
TradingSymbol
NMRD
CY2022Q2 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q2 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q2 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q2 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q2 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q2 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q2 dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24102866 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14751833 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17749233 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
1105496 usd
CY2022Q1 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
750167 usd
CY2022Q2 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
217510 usd
CY2022Q1 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
101297 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
1625156 usd
CY2022Q1 us-gaap Inventory Net
InventoryNet
1487771 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
17699995 usd
CY2022Q1 us-gaap Assets Current
AssetsCurrent
20088468 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
603130 usd
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
532508 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1411919 usd
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1480980 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2015049 usd
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2013488 usd
CY2022Q2 us-gaap Assets
Assets
19715044 usd
CY2021Q2 us-gaap Gross Profit
GrossProfit
0 usd
CY2022Q1 us-gaap Assets
Assets
22101956 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
92701 usd
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
136310 usd
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1491498 usd
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
998622 usd
CY2022Q2 us-gaap Notes Payable Current
NotesPayableCurrent
16186387 usd
CY2022Q1 us-gaap Notes Payable Current
NotesPayableCurrent
19188724 usd
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
177772 usd
CY2022Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
259256 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17948358 usd
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
20582912 usd
CY2022Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
4699660 usd
CY2022Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
0 usd
CY2022Q2 us-gaap Deferred Revenue And Credits Noncurrent
DeferredRevenueAndCreditsNoncurrent
1025176 usd
CY2022Q1 us-gaap Deferred Revenue And Credits Noncurrent
DeferredRevenueAndCreditsNoncurrent
1052960 usd
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5724836 usd
CY2022Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1052960 usd
CY2022Q2 us-gaap Liabilities
Liabilities
23673194 usd
CY2022Q1 us-gaap Liabilities
Liabilities
21635872 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
42000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
42000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24102866 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24102866 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24102866 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24102866 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
24103 usd
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
24103 usd
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
38295775 usd
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
38295775 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41710773 usd
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-37731476 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-567255 usd
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-122318 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3958150 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
466084 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19715044 usd
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22101956 usd
CY2022Q2 us-gaap Revenues
Revenues
0 usd
CY2021Q2 us-gaap Revenues
Revenues
0 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 usd
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
0 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
330055 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
288484 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1880938 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1332185 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
2210993 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
1620669 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2210993 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1620669 usd
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1768304 usd
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1723056 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3979297 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3343725 usd
CY2022Q2 us-gaap Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax
TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax
-444937 usd
CY2021Q2 us-gaap Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax
TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax
-10706 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4424234 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3354431 usd
CY2022Q2 nmrd Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-0.17
CY2021Q2 nmrd Net Loss Per Share Basic And Diluted
NetLossPerShareBasicAndDiluted
-0.14
CY2022Q2 nmrd Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
24102866 shares
CY2021Q2 nmrd Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
23109897 shares
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
466084 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
-444937 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3979297 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-3958150 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
8358172 usd
CY2021Q2 nmrd Exercise Of Warrants Amount
ExerciseOfWarrantsAmount
2963658 usd
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
-10706 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3343725 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
7967399 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3979297 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3343725 usd
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
98792 usd
CY2021Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
36133 usd
CY2022Q2 us-gaap Accretion Expense
AccretionExpense
1768304 usd
CY2021Q2 us-gaap Accretion Expense
AccretionExpense
1723056 usd
CY2022Q2 nmrd Marktomarket Fx Revaluation
MarktomarketFxRevaluation
613687 usd
CY2021Q2 nmrd Marktomarket Fx Revaluation
MarktomarketFxRevaluation
0 usd
CY2022Q2 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
355329 usd
CY2021Q2 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
550211 usd
CY2022Q2 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
137386 usd
CY2021Q2 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
31583 usd
CY2022Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-43609 usd
CY2021Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-145898 usd
CY2022Q2 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-116214 usd
CY2021Q2 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-256583 usd
CY2022Q2 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-120812 usd
CY2021Q2 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1500000 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-74282 usd
CY2021Q2 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
363052 usd
CY2022Q2 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-112279 usd
CY2021Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1463658 usd
CY2021Q2 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
515731 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2384143 usd
CY2021Q2 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
22714 usd
CY2022Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
CY2021Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1690028 usd
CY2022Q2 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
192114 usd
CY2021Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2963658 usd
CY2022Q2 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4774282 usd
CY2022Q2 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
-0 usd
CY2021Q2 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
293285 usd
CY2022Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25598 usd
CY2021Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
82222 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-217712 usd
CY2021Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-398221 usd
CY2022Q2 nmrd Commission Paid On Note Payable
CommissionPaidOnNotePayable
-4700000 usd
CY2021Q2 nmrd Commission Paid On Note Payable
CommissionPaidOnNotePayable
-0 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2676137 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-624591 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-321263 usd
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
18973 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17749233 usd
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31865371 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14751833 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31259753 usd
CY2022Q2 nmrd Prepayment Of Equity Compensation
PrepaymentOfEquityCompensation
0 usd
CY2021Q2 nmrd Prepayment Of Equity Compensation
PrepaymentOfEquityCompensation
25000 usd
CY2022Q2 nmrd Monitoring Fees Added To Notes Payable
MonitoringFeesAddedToNotesPayable
522462 usd
CY2021Q2 nmrd Monitoring Fees Added To Notes Payable
MonitoringFeesAddedToNotesPayable
0 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41710773 usd
CY2022Q2 us-gaap Cash
Cash
14751833 usd
CY2014Q1 us-gaap Advance Royalties
AdvanceRoyalties
1000000 gbp
CY2022Q2 us-gaap Advance Royalties
AdvanceRoyalties
1200000 usd
CY2022Q1 us-gaap Advance Royalties
AdvanceRoyalties
1310000 usd
CY2022Q2 us-gaap Deferred Revenue
DeferredRevenue
178000 usd
CY2022Q1 us-gaap Deferred Revenue
DeferredRevenue
259000 usd
CY2022Q2 nmrd Related Party Transaction Due From To Related Partie
RelatedPartyTransactionDueFromToRelatedPartie
-101297 usd
CY2021Q2 nmrd Related Party Transaction Due From To Related Partie
RelatedPartyTransactionDueFromToRelatedPartie
148795 usd
CY2022 nmrd Related Party Transaction Due From To Related Partie
RelatedPartyTransactionDueFromToRelatedPartie
148795 usd
CY2022Q2 nmrd Amount Invoiced By Pharma To Ddl And Tcl
AmountInvoicedByPharmaToDdlAndTcl
949713 usd
CY2021Q2 nmrd Amount Invoiced By Pharma To Ddl And Tcl
AmountInvoicedByPharmaToDdlAndTcl
597594 usd
CY2022 nmrd Amount Invoiced By Pharma To Ddl And Tcl
AmountInvoicedByPharmaToDdlAndTcl
3245985 usd
CY2022Q2 nmrd Amounts Invoiced By Ddl To Pharma
AmountsInvoicedByDdlToPharma
0 usd
CY2021Q2 nmrd Amounts Invoiced By Ddl To Pharma
AmountsInvoicedByDdlToPharma
0 usd
CY2022 nmrd Amounts Invoiced By Ddl To Pharma
AmountsInvoicedByDdlToPharma
-2495 usd
CY2022Q2 nmrd Amounts Repaid By Ddl To Pharma
AmountsRepaidByDdlToPharma
-1074796 usd
CY2021Q2 nmrd Amounts Repaid By Ddl To Pharma
AmountsRepaidByDdlToPharma
-856904 usd
CY2022 nmrd Amounts Repaid By Ddl To Pharma
AmountsRepaidByDdlToPharma
-3492962 usd
CY2022Q2 nmrd Foreign Currency Translation Related Party
ForeignCurrencyTranslationRelatedParty
8870 usd
CY2021Q2 nmrd Foreign Currency Translation Related Party
ForeignCurrencyTranslationRelatedParty
2727 usd
CY2022 nmrd Foreign Currency Translation Related Party
ForeignCurrencyTranslationRelatedParty
-620 usd
CY2022Q2 nmrd Related Party Transaction Due From To Related Parties
RelatedPartyTransactionDueFromToRelatedParties
-217510 usd
CY2021Q2 nmrd Related Party Transaction Due From To Related Parties
RelatedPartyTransactionDueFromToRelatedParties
-107788 usd
CY2022 nmrd Related Party Transaction Due From To Related Parties
RelatedPartyTransactionDueFromToRelatedParties
-101297 usd
CY2021Q1 us-gaap Payments For Advance To Affiliate
PaymentsForAdvanceToAffiliate
15000 usd
CY2022Q2 us-gaap Capital Leases Future Minimum Payments Receivable In Two Years
CapitalLeasesFutureMinimumPaymentsReceivableInTwoYears
16186387 usd
CY2022Q2 us-gaap Capital Leases Future Minimum Payments Receivable In Three Years
CapitalLeasesFutureMinimumPaymentsReceivableInThreeYears
4699660 usd
CY2022Q2 us-gaap Capital Leases Future Minimum Payments Receivable Due Thereafter
CapitalLeasesFutureMinimumPaymentsReceivableDueThereafter
20886047 usd
CY2022Q2 nmrd Warrants Exercised
WarrantsExercised
0 shares
CY2022Q2 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
0 shares
CY2021Q2 nmrd Warrants Exercised
WarrantsExercised
366892 shares
CY2021Q2 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2963658 usd
CY2021Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1573098 usd
CY2021Q2 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
0 shares
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3979297 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3343725 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24102866 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23109897 shares
CY2022Q2 nmrd Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.17
CY2021Q2 nmrd Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.14
CY2022Q2 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
1573098 usd
CY2021Q2 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
1940740 usd

Files In Submission

Name View Source Status
0001079973-22-000965-index-headers.html Edgar Link pending
0001079973-22-000965-index.html Edgar Link pending
0001079973-22-000965.txt Edgar Link pending
0001079973-22-000965-xbrl.zip Edgar Link pending
ex31x1.htm Edgar Link pending
ex31x2.htm Edgar Link pending
ex32x1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nmra_10q-063022.htm Edgar Link pending
nmrd-20220630.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nmrd-20220630_def.xml Edgar Link unprocessable
nmrd-20220630_lab.xml Edgar Link unprocessable
nmrd-20220630_pre.xml Edgar Link unprocessable
nmra_10q-063022_htm.xml Edgar Link completed
nmrd-20220630_cal.xml Edgar Link unprocessable